The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the coronavirus disease 2019 (COVID-19) pandemic. Here, we quantified levels of SARS-CoV-2-reactive antibodies and hCoV-reactive antibodies in serum samples collected from 431 humans before the COVID-19 pandemic. We then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS-CoV-2. Finally, we longitudinally measured hCoV and SARS-CoV-2 antibodies in the serum of hospitalized COVID-19 patients. Our studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic. We determined that ∼20% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS-CoV-2 spike and nucleocapsid proteins. These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but they were boosted upon SARS-CoV-2 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Woo, P. C. Y., Lau, S. K. P., Chu, C.-M., Chan, K.-H., Tsoi, H.-W., Huang, Y., Wong, B. H. L., Poon, R. W. S., Cai, J. J., Luk, W.-K., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.884-895.2005 · Cited by 1,525
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509
Self-citationSARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Self-citationPreexisting and de novo humoral immunity to SARS-CoV-2 in humans
Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science · doi:10.1126/science.abe1107 · Cited by 886
Seasonal coronavirus protective immunity is short-lasting
Edridge, A. W. D., Kaczorowska, J., Hoste, A. C. R., Bakker, M., Klein, M., Loens, K., Jebbink, M. F., Matser, A., Kinsella, C. M., Rueda, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1083-1 · Cited by 767
Gaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P., & Templeton, K. E. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00636-10 · Cited by 699
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
Shrock, E., Fujimura, E., Kula, T., Timms, R. T., Lee, I.-H., Leng, Y., Robinson, M. L., Sie, B. M., Li, M. Z., Chen, Y., et al. (2020) · Science · doi:10.1126/science.abd4250 · Cited by 678 · cited 2×
“SARS-CoV-2 boosts antibodies reactive to other human betacoronaviruses Recent studies indicate that COVID-19-recovered donors possess higher levels of antibodies against seasonal betacoronaviruses (Nguyen-Contant et al., 2020; (Shrock et al., 2020)).”
Jaimes, J. A., André, N. M., Chappie, J. S., Millet, J. K., & Whittaker, G. R. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.04.009 · Cited by 491
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells
Schulien, I., Kemming, J., Oberhardt, V., Wild, K., Seidel, L. M., Killmer, S., Sagar, Daul, F., Salvat Lago, M., Decker, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01143-2 · Cited by 357
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns
Sette, A., & Crotty, S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0389-z · Cited by 347
Recent endemic coronavirus infection is associated with less severe COVID-19
Sagar, M., Reifler, K., Rossi, M., Miller, N. S., Sinha, P., White, L. F., & Mizgerd, J. P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143380 · Cited by 324
Human coronavirus circulation in the United States 2014–2017
Killerby, M. E., Biggs, H. M., Haynes, A., Dahl, R. M., Mustaquim, D., Gerber, S. I., & Watson, J. T. (2018) · Journal of Clinical Virology · doi:10.1016/j.jcv.2018.01.019 · Cited by 298
Vijgen, L., Keyaerts, E., Lemey, P., Maes, P., Van Reeth, K., Nauwynck, H., Pensaert, M., & Van Ranst, M. (2006) · Journal of Virology · doi:10.1128/jvi.02675-05 · Cited by 270
Wu, A., Mihaylova, V. T., Landry, M. L., & Foxman, E. F. (2020) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30114-2 · Cited by 264
Pfefferle, S., Oppong, S., Drexler, J. F., Gloza-Rausch, F., Ipsen, A., Seebens, A., Müller, M. A., Annan, A., Vallo, P., Adu-Sarkodie, Y., et al. (2009) · Emerging Infectious Diseases · doi:10.3201/eid1509.090224 · Cited by 249
Immune history and influenza virus susceptibility
Cobey, S., & Hensley, S. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.12.004 · Cited by 244
Self-citationNguyen-Contant, P., Embong, A. K., Kanagaiah, P., Chaves, F. A., Yang, H., Branche, A. R., Topham, D. J., & Sangster, M. Y. (2020) · mBio · doi:10.1128/mbio.01991-20 · Cited by 204
The dominance of human coronavirus OC43 and NL63 infections in infants
Dijkman, R., Jebbink, M. F., Gaunt, E., Rossen, J. W. A., Templeton, K. E., Kuijpers, T. W., & van der Hoek, L. (2012) · Journal of Clinical Virology · doi:10.1016/j.jcv.2011.11.011 · Cited by 190
Mosaic Structure of Human Coronavirus NL63, One Thousand Years of Evolution
Pyrc, K., Dijkman, R., Deng, L., Jebbink, M. F., Ross, H. A., Berkhout, B., & van der Hoek, L. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.09.074 · Cited by 183
SARS-CoV-2 seroprevalence among parturient women in Philadelphia
Flannery, D. D., Gouma, S., Dhudasia, M. B., Mukhopadhyay, S., Pfeifer, M. R., Woodford, E. C., Gerber, J. S., Arevalo, C. P., Bolton, M. J., Weirick, M. E., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd5709 · Cited by 125
Self-citationFriedman, N., Alter, H., Hindiyeh, M. Y., Mendelson, E., Avni, Y. S., & Mandelboim, M. (2018) · Viruses · doi:10.3390/v10100515 · Cited by 110
Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies
Arevalo, C. P., Sage, V. L., Bolton, M. J., Eilola, T., Jones, J. E., Kormuth, K. A., Nturibi, E. M., Balmaseda, Á., Gordon, A., Lakdawala, S. S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1920321117 · Cited by 94
Self-citationPoston, D., Weisblum, Y., Wise, H. M., Templeton, K. E., Jenks, S. J., Hatziioannou, T., & Bieniasz, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1803 · Cited by 83
Anderson, E. M., Diorio, C. J., Goodwin, E. C., McNerney, K. O., Weirick, M. E., Gouma, S., Bolton, M. J., Arevalo, C. P., Chase, J. M., Hicks, P. D., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa161 · Cited by 74
Self-citationMiddle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility
Gouma, S., Kim, K., Weirick, M. E., Gumina, M. E., Branche, A. R., Topham, D. J., Martin, E. T., Monto, A. S., Cobey, S. E., & Hensley, S. E. (2020) · Nature Communications · doi:10.1038/s41467-020-18465-x · Cited by 67
Self-citation
Research works printed but not linked: 2
- Anderson, 2020, SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19, J. Pediatric Infect. Dis. Soc., piaa161
- Poston, 2020, Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera from individuals with recent seasonal coronavirus infection, Clin. Infect. Dis., ciaa1803
Cited by
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Immune determinants of COVID-19 disease presentation and severity
Brodin, P. (2021) · Nature Medicine · doi:10.1038/s41591-020-01202-8 · Cited by 663
The first 12 months of COVID-19: a timeline of immunological insights
Carvalho, T., Krammer, F., & Iwasaki, A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00522-1 · Cited by 443
After the pandemic: perspectives on the future trajectory of COVID-19
Telenti, A., Arvin, A., Corey, L., Corti, D., Diamond, M. S., García-Sastre, A., Garry, R. F., Holmes, E. C., Pang, P. S., & Virgin, H. W. (2021) · Nature · doi:10.1038/s41586-021-03792-w · Cited by 426
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2
Swadling, L., Diniz, M. O., Schmidt, N. M., Amin, O. E., Chandran, A., Shaw, E., Pade, C., Gibbons, J. M., Le Bert, N., Tan, A. T., et al. (2022) · Nature · doi:10.1038/s41586-021-04186-8 · Cited by 405
Metadata
- Authors
- Anderson, E. M., Goodwin, E. C., Verma, A., Arevalo, C. P., Bolton, M. J., Weirick, M. E., Gouma, S., McAllister, C. M., Christensen, S. R., Weaver, J., Hicks, P., Manzoni, T. B., Oniyide, O., Ramage, H., Mathew, D., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., D’Andrea, K., Kuthuru, O., Dougherty, J., Pattekar, A., Kim, J., Han, N., Apostolidis, S. A., Huang, A. C., Vella, L. A., Kuri-Cervantes, L., Pampena, M. B., Betts, M. R., Wherry, E. J., Meyer, N. J., Cherry, S., Bates, P., Rader, D. J., & Hensley, S. E.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 184
- Issue
- 7
- Pages
- 1858-1864.e10
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W3126847903
- Cited by
- 388
- References
- 32
- FWCI
- 25.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- NIH
- US Department of Defense
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.